Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 6, 2014, Pages 879-886

  Blondon, M ^a,b   van Hylckama Vlieg, A ^c   Wiggins, K L ^a   Harrington, L B ^a   Mcknight, B ^a   Rice, K M ^a   Rosendaal, F R ^c   Heckbert, S R ^a,d   Psaty, B M ^a,d   Smith, N L ^a,d,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Estradiol; Estrogen replacement therapy; Estrogens; Hemostasis; Thromboembolism; Venous thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PROTEIN S; BIOLOGICAL MARKER; THROMBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HEMODYNAMIC PARAMETERS; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; ESTROGEN THERAPY; HEMOSTASIS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; AGED; ANTITHROMBINS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FACTOR VII; FEMALE; HEMOSTASIS; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROTEIN S; RISK FACTORS; THROMBIN; VENOUS THROMBOSIS;

EID: 84902120671     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12560     Document Type: Article

References (35)

1. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States. Menopause 2012; 19: 616-21.
2. Fournier A, Kernaleguen C, Panjo H, Clavel-Chapelon F, Ringa V. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause 2011; 18: 219-23.
3. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.
4. Curb JD, Prentice RL, Bray PF, Langer RD, van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772-80.
5. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610-20.
6. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014; 174: 25-31.
7. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-9.
8. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
9. Heckbert SR, Wiggins KL, Glazer NL, Dublin S, Psaty BM, Smith NL, Longstreth WT, Lumley T. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538-44.
10. Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth WT. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med 2002; 162: 1954-60.
11. Heckbert SR, Weiss NS, Koepsell TD, Lemaitre RN, Smith NL, Siscovick DS, Lin D, Psaty BM. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997; 157: 1330-6.
12. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001; 86: 1495-500.
13. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35: 18S-24S.
14. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19: 257-71.
15. Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, Ballieux B, van Vliet H. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012; 10: 992-7.
16. Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M. Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 2000; 7: 243-50.
17. Dielis AWJH, Castoldi E, Spronk HMH, van Oerle R, Hamulyák K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-31.
18. Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 2009; 7: 1639-48.
19. van HylckamaVlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138: 769-74.
20. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
21. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-5.
22. Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Reiner AP, Lumley T, Meijers JCM, Psaty BM, Rosendaal FR. The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. J Thromb Haemost 2006; 4: 1701-6.
23. Post MS, Rosing J, van der Mooren MJ, Zweegman S, van Baal WM, Kenemans P, Stehouwer CDA. Ageing Women' and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU). Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002; 119: 1017-23.
24. Høibraaten E, Mowinckel MC, de Ronde H, Bertina RM, SANDSET PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-20.
25. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010; 126: 5-11.
26. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
27. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
28. Scarabin P-Y, Hemker HC, Clément C, Soisson V, Alhenc-Gelas M. Increased thrombin generation among postmenopausal women using hormone therapy. Menopause 2011; 18: 873-9.
29. Bagot CN, Marsh MS, Whitehead M, Sherwood R, Roberts L, Patel RK, Arya R. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010; 8: 1736-44.
30. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO; Prospective Collaborative Danish Climacteric Study. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG 2003; 110: 541-7.
31. Post MS, Christella M, Thomassen LGD, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CDA. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-21.
32. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
33. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-20.
34. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001; 184: 255-63.
35. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-36.